Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Conditions
Non Small Cell Lung Cancer · Solid Tumors, Adult · Lung Cancer · Lung Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UCLA Hematology/Oncology, Santa Monica, California, United States
Contact: Principal Investigator (Jonathan Goldman, MD)SCRI at HealthOne, Denver, Colorado, United States
Contact: Principal Investigator (Gerald Falchook, MD)Florida Cancer Specialists, Sarasota, Florida, United States
Contact: Principal Investigator (Judy Wang, MD)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Mark Awad, MD, PhD)Henry Ford Health System, Detroit, Michigan, United States
Contact: Principal Investigator (Shiresh Gadgeel, MD)START MidWest, Grand Rapids, Michigan, United States
Contact: Principal Investigator (Manish Sharma, MD)NYU Langone Hematology Oncology Associates-Mineola, Mineola, New York, United States
Contact: Principal Investigator (Salman Punekar, MD)New York University Langone Health, New York, New York, United States
Contact: Principal Investigator (Salman Punekar, MD)Sarah Cannon Tennessee Oncology, Nashville, Tennessee, United States
Contact: Principal Investigator (David Spigel, MD)US Oncology Investigational Products Center, Dallas, Texas, United States
Contact: Principal Investigator (Kartik Konduri, MD)The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Ferdinandos Skoulidis, MD)NEXT Oncology Virginia, Fairfax, Virginia, United States
Contact: Principal Investigator (Alex Spira, MD)US Oncology Investigational Products Center, Norfolk, Virginia, United States
Contact: Principal Investigator (Jedrzej Wykretowicz, MD)
Study leads
Adam Crystal, MD, PhD
Study Director
Tango Therapeutics, Inc.